Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ

Wyszukujesz frazę ""Oncogene Proteins, Fusion"" wg kryterium: Temat


Tytuł :
Patient-driven discovery and post-clinical validation of NTRK3 fusion as an acquired resistance mechanism to selpercatinib in RET fusion-positive lung cancer.
Autorzy :
Subbiah V; Department of Investigational Cancer Therapeutics, University of Texas MD Anderson Cancer Center, Houston, USA. Electronic address: .
Shen T; Peggy and Charles Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, USA; Department of Pathology, University of Oklahoma Health Sciences Center, Oklahoma City, USA.
Tetzlaff M; Department of Anatomical Pathology, University of Texas MD Anderson Cancer Center, Houston, USA.
Weissferdt A; Department of Anatomical Pathology, University of Texas MD Anderson Cancer Center, Houston, USA.
Byers LA; Department of Thoracic-Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, USA.
Cascone T; Department of Thoracic-Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, USA.
Behrang A; Division of Radiology, University of Texas MD Anderson Cancer Center, Houston, USA.
Meric-Bernstam F; Department of Investigational Cancer Therapeutics, University of Texas MD Anderson Cancer Center, Houston, USA.
Mooers BHM; Peggy and Charles Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, USA; Department of Biochemistry and Molecular Biology, University of Oklahoma Health Sciences Center, Oklahoma City, USA.
Rothenberg SM; Loxo Oncology at Lilly, Stamford, USA.
Ebata K; Loxo Oncology at Lilly, Stamford, USA. Electronic address: .
Wu J; Peggy and Charles Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, USA; Department of Pathology, University of Oklahoma Health Sciences Center, Oklahoma City, USA. Electronic address: .
Pokaż więcej
Źródło :
Annals of oncology : official journal of the European Society for Medical Oncology [Ann Oncol] 2021 Jun; Vol. 32 (6), pp. 817-819. Date of Electronic Publication: 2021 Feb 20.
Typ publikacji :
Letter; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms :
Lung Neoplasms*/drug therapy
Lung Neoplasms*/genetics
Oncogene Proteins, Fusion*/genetics
Proto-Oncogene Proteins c-ret*/genetics
Receptor, trkC*/genetics
Humans ; Protein Kinase Inhibitors/therapeutic use ; Pyrazoles ; Pyridines
Raport
Tytuł :
Fusion genes as biomarkers in pediatric cancers: A review of the current state and applicability in diagnostics and personalized therapy.
Autorzy :
Vellichirammal NN; Department of Genetics, Cell Biology, and Anatomy, University of Nebraska Medical Center, Omaha, NE, 68198, USA. Electronic address: .
Chaturvedi NK; Department of Pediatrics, Hematology, and Oncology, University of Nebraska Medical Center, Omaha, NE, 68198, USA.
Joshi SS; Department of Genetics, Cell Biology, and Anatomy, University of Nebraska Medical Center, Omaha, NE, 68198, USA.
Coulter DW; Department of Pediatrics, Hematology, and Oncology, University of Nebraska Medical Center, Omaha, NE, 68198, USA.
Guda C; Department of Genetics, Cell Biology, and Anatomy, University of Nebraska Medical Center, Omaha, NE, 68198, USA. Electronic address: .
Pokaż więcej
Źródło :
Cancer letters [Cancer Lett] 2021 Feb 28; Vol. 499, pp. 24-38. Date of Electronic Publication: 2020 Nov 25.
Typ publikacji :
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Review
MeSH Terms :
Antineoplastic Agents/*therapeutic use
Biomarkers, Tumor/*genetics
Early Detection of Cancer/*methods
Neoplasms/*diagnosis
Oncogene Proteins, Fusion/*genetics
Antineoplastic Agents/pharmacology ; Biomarkers, Tumor/antagonists & inhibitors ; Biomarkers, Tumor/blood ; Child ; Circulating Tumor DNA/blood ; Circulating Tumor DNA/genetics ; Drug Monitoring/methods ; Genetic Testing/methods ; Genomics/methods ; High-Throughput Nucleotide Sequencing ; Humans ; Liquid Biopsy/methods ; Neoplasms/blood ; Neoplasms/drug therapy ; Neoplasms/genetics ; Oncogene Proteins, Fusion/antagonists & inhibitors ; Oncogene Proteins, Fusion/blood ; Precision Medicine/methods ; Treatment Outcome
Czasopismo naukowe
Tytuł :
Biomolecular condensation of NUP98 fusion proteins drives leukemogenic gene expression.
Autorzy :
Terlecki-Zaniewicz S; Institute for Medical Biochemistry, University of Veterinary Medicine, Vienna, Austria.; Children's Cancer Research Institute, St. Anna Kinderkrebsforschung, Vienna, Austria.
Humer T; Institute for Medical Biochemistry, University of Veterinary Medicine, Vienna, Austria.
Eder T; Institute for Medical Biochemistry, University of Veterinary Medicine, Vienna, Austria.
Schmoellerl J; Institute for Medical Biochemistry, University of Veterinary Medicine, Vienna, Austria.
Heyes E; Institute for Medical Biochemistry, University of Veterinary Medicine, Vienna, Austria.
Manhart G; Institute for Medical Biochemistry, University of Veterinary Medicine, Vienna, Austria.
Kuchynka N; Ludwig Boltzmann Institute for Cancer Research, Vienna, Austria.
Parapatics K; CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria.
Liberante FG; Institute for Medical Biochemistry, University of Veterinary Medicine, Vienna, Austria.
Müller AC; CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria.
Tomazou EM; Children's Cancer Research Institute, St. Anna Kinderkrebsforschung, Vienna, Austria.
Grebien F; Institute for Medical Biochemistry, University of Veterinary Medicine, Vienna, Austria. .
Pokaż więcej
Źródło :
Nature structural & molecular biology [Nat Struct Mol Biol] 2021 Feb; Vol. 28 (2), pp. 190-201. Date of Electronic Publication: 2021 Jan 21.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Homeodomain Proteins*/chemistry
Homeodomain Proteins*/physiology
Leukemia*/metabolism
Leukemia*/pathology
Nuclear Pore Complex Proteins*/chemistry
Nuclear Pore Complex Proteins*/physiology
Oncogene Proteins, Fusion*/chemistry
Oncogene Proteins, Fusion*/physiology
Cell Nucleus/*metabolism
Animals ; Gene Expression ; Gene Expression Regulation, Leukemic ; HEK293 Cells ; HL-60 Cells ; Humans ; Mice ; NIH 3T3 Cells
Czasopismo naukowe
Tytuł :
PCAT: an integrated portal for genomic and preclinical testing data of pediatric cancer patient-derived xenograft models.
Autorzy :
Yang J; Greehey Children's Cancer Research Institute, University of Texas Health at San Antonio, San Antonio, TX 78229, USA.
Li Q; Greehey Children's Cancer Research Institute, University of Texas Health at San Antonio, San Antonio, TX 78229, USA.
Noureen N; Greehey Children's Cancer Research Institute, University of Texas Health at San Antonio, San Antonio, TX 78229, USA.
Fang Y; Greehey Children's Cancer Research Institute, University of Texas Health at San Antonio, San Antonio, TX 78229, USA.; School of Natural Science, University of Texas at Austin, Austin, TX 78712, USA.
Kurmasheva R; Greehey Children's Cancer Research Institute, University of Texas Health at San Antonio, San Antonio, TX 78229, USA.; Department of Molecular Medicine, University of Texas Health at San Antonio, San Antonio, TX 78229, USA.
Houghton PJ; Greehey Children's Cancer Research Institute, University of Texas Health at San Antonio, San Antonio, TX 78229, USA.; Department of Molecular Medicine, University of Texas Health at San Antonio, San Antonio, TX 78229, USA.
Wang X; Greehey Children's Cancer Research Institute, University of Texas Health at San Antonio, San Antonio, TX 78229, USA.; Department of Population Health Sciences, University of Texas Health at San Antonio, San Antonio, TX 78229, USA.
Zheng S; Greehey Children's Cancer Research Institute, University of Texas Health at San Antonio, San Antonio, TX 78229, USA.; Department of Population Health Sciences, University of Texas Health at San Antonio, San Antonio, TX 78229, USA.
Pokaż więcej
Źródło :
Nucleic acids research [Nucleic Acids Res] 2021 Jan 08; Vol. 49 (D1), pp. D1321-D1327.
Typ publikacji :
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
MeSH Terms :
Gene Expression Regulation, Neoplastic*
Software*
Antineoplastic Agents/*therapeutic use
Neoplasms/*genetics
Oncogene Proteins, Fusion/*genetics
Animals ; Child ; DNA Copy Number Variations/drug effects ; Data Mining ; Databases, Genetic ; Disease Models, Animal ; Genomics/methods ; Heterografts ; Humans ; Internet ; Mutation ; Neoplasms/drug therapy ; Neoplasms/mortality ; Neoplasms/pathology ; Oncogene Proteins, Fusion/antagonists & inhibitors ; Oncogene Proteins, Fusion/metabolism ; Prognosis ; Survival Analysis ; Xenograft Model Antitumor Assays
Czasopismo naukowe
Tytuł :
EML4-ALK induces cellular senescence in mortal normal human cells and promotes anchorage-independent growth in hTERT-transduced normal human cells.
Autorzy :
Miyanaga A; Laboratory of Human Carcinogenesis, Center for Cancer Research, National Cancer Institute, National Institutes of Health, 37 Convent Drive, Room 3068A, Bethesda, MD, 20892, USA.; Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, Tokyo, Japan.
Matsumoto M; Laboratory of Human Carcinogenesis, Center for Cancer Research, National Cancer Institute, National Institutes of Health, 37 Convent Drive, Room 3068A, Bethesda, MD, 20892, USA.; Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, Tokyo, Japan.
Beck JA; Laboratory of Human Carcinogenesis, Center for Cancer Research, National Cancer Institute, National Institutes of Health, 37 Convent Drive, Room 3068A, Bethesda, MD, 20892, USA.
Horikawa I; Laboratory of Human Carcinogenesis, Center for Cancer Research, National Cancer Institute, National Institutes of Health, 37 Convent Drive, Room 3068A, Bethesda, MD, 20892, USA.
Oike T; Laboratory of Human Carcinogenesis, Center for Cancer Research, National Cancer Institute, National Institutes of Health, 37 Convent Drive, Room 3068A, Bethesda, MD, 20892, USA.
Okayama H; Laboratory of Human Carcinogenesis, Center for Cancer Research, National Cancer Institute, National Institutes of Health, 37 Convent Drive, Room 3068A, Bethesda, MD, 20892, USA.
Tanaka H; Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, Indiana, USA.
Burkett SS; Molecular Cytogenetic Core Facility, Mouse Cancer Genetics Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, MD, USA.
Robles AI; Laboratory of Human Carcinogenesis, Center for Cancer Research, National Cancer Institute, National Institutes of Health, 37 Convent Drive, Room 3068A, Bethesda, MD, 20892, USA.
Khan M; Laboratory of Human Carcinogenesis, Center for Cancer Research, National Cancer Institute, National Institutes of Health, 37 Convent Drive, Room 3068A, Bethesda, MD, 20892, USA.
Lissa D; Laboratory of Human Carcinogenesis, Center for Cancer Research, National Cancer Institute, National Institutes of Health, 37 Convent Drive, Room 3068A, Bethesda, MD, 20892, USA.
Seike M; Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, Tokyo, Japan.
Gemma A; Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, Tokyo, Japan.
Mano H; Division of Cellular Signaling, National Cancer Center Research Institute, Tokyo, Japan.
Harris CC; Laboratory of Human Carcinogenesis, Center for Cancer Research, National Cancer Institute, National Institutes of Health, 37 Convent Drive, Room 3068A, Bethesda, MD, 20892, USA. .
Pokaż więcej
Źródło :
BMC cancer [BMC Cancer] 2021 Mar 24; Vol. 21 (1), pp. 310. Date of Electronic Publication: 2021 Mar 24.
Typ publikacji :
Journal Article
MeSH Terms :
Carcinogenesis/*genetics
Carcinoma, Non-Small-Cell Lung/*genetics
Lung Neoplasms/*genetics
Oncogene Proteins, Fusion/*metabolism
Telomerase/*metabolism
Animals ; Carcinogenesis/pathology ; Carcinoma, Non-Small-Cell Lung/pathology ; Cell Line ; Cell Proliferation/genetics ; Cellular Senescence/genetics ; DNA Damage ; Disease Models, Animal ; Epithelial Cells ; Female ; Fibroblasts ; Gene Expression Regulation, Neoplastic ; Genetic Vectors/genetics ; Humans ; Lentivirus/genetics ; Lung Neoplasms/pathology ; Mice ; Oncogene Proteins, Fusion/genetics ; RNA-Seq ; Telomerase/genetics ; Telomere Homeostasis/genetics ; Transfection
Czasopismo naukowe
Tytuł :
Covid-19 pathogenesis in prostatic cancer and TMPRSS2-ERG regulatory genetic pathway.
Autorzy :
Afshari A; Shiraz Nephro-Urology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran; Shiraz Transplant Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
Janfeshan S; Shiraz Nephro-Urology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
Yaghobi R; Shiraz Nephro-Urology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran; Shiraz Transplant Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
Roozbeh J; Shiraz Nephro-Urology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran. Electronic address: .
Azarpira N; Shiraz Transplant Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
Pokaż więcej
Źródło :
Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases [Infect Genet Evol] 2021 Mar; Vol. 88, pp. 104669. Date of Electronic Publication: 2020 Dec 07.
Typ publikacji :
Journal Article; Review
MeSH Terms :
Angiotensin-Converting Enzyme 2/*genetics
COVID-19/*genetics
Oncogene Proteins, Fusion/*genetics
Prostatic Neoplasms/*genetics
Serine Endopeptidases/*genetics
Spike Glycoprotein, Coronavirus/*genetics
Aged ; Angiotensin-Converting Enzyme 2/metabolism ; COVID-19/complications ; COVID-19/pathology ; COVID-19/virology ; Dihydrotestosterone/metabolism ; Gene Expression Regulation ; Host-Pathogen Interactions/genetics ; Humans ; Male ; Oncogene Proteins, Fusion/metabolism ; Prostatic Neoplasms/complications ; Prostatic Neoplasms/pathology ; Prostatic Neoplasms/virology ; Receptors, Androgen/genetics ; Receptors, Androgen/metabolism ; SARS-CoV-2/genetics ; SARS-CoV-2/metabolism ; SARS-CoV-2/pathogenicity ; Serine Endopeptidases/metabolism ; Signal Transduction ; Spike Glycoprotein, Coronavirus/metabolism ; Transcription, Genetic ; Virus Internalization
Czasopismo naukowe
Tytuł :
Fusion of the CRM1 nuclear export receptor to AF10 causes leukemia and transcriptional activation of HOXA genes.
Autorzy :
Aumann WK; Aflac Cancer & Blood Disorders Center, Children's Healthcare of Atlanta, Atlanta, GA, USA.; Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, USA.
Heath JL; Department of Pediatrics, Biochemistry, University of Vermont; University of Vermont Children's Hospital; Vermont Cancer Center, Burlington, VT, USA.
Conway AE; National Institute of Environmental Health Sciences (NIEHS), Research Triangle Park, Durham, NC, USA.
Sze SK; Maine Children's Cancer Program, Scarborough, ME, USA.
Gupta VK; Department of Pediatrics, Division of Pediatric Hematology-Oncology, Duke University Medical Center, Durham, NC, USA.
Kazi RR; Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, USA.
Tope DR; Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, USA.
Wechsler DS; Aflac Cancer & Blood Disorders Center, Children's Healthcare of Atlanta, Atlanta, GA, USA. .; Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, USA. .
Lavau CP; Department of Neurosurgery, Duke University Medical Center, Durham, NC, USA. .
Pokaż więcej
Źródło :
Leukemia [Leukemia] 2021 Mar; Vol. 35 (3), pp. 876-880. Date of Electronic Publication: 2020 Jul 30.
Typ publikacji :
Letter; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms :
Transcriptional Activation*
Hematopoietic Stem Cells/*pathology
Homeodomain Proteins/*genetics
Karyopherins/*metabolism
Leukemia, Experimental/*pathology
Oncogene Proteins, Fusion/*metabolism
Receptors, Cytoplasmic and Nuclear/*metabolism
Transcription Factors/*metabolism
Active Transport, Cell Nucleus ; Animals ; Apoptosis ; Cell Proliferation ; Cells, Cultured ; Gene Expression Regulation, Leukemic ; Hematopoietic Stem Cells/metabolism ; Homeodomain Proteins/metabolism ; Karyopherins/genetics ; Leukemia, Experimental/etiology ; Leukemia, Experimental/metabolism ; Mice ; Oncogene Proteins, Fusion/genetics ; Receptors, Cytoplasmic and Nuclear/genetics ; Transcription Factors/genetics
Raport
Tytuł :
Definition of a small core transcriptional circuit regulated by AML1-ETO.
Autorzy :
Stengel KR; Department of Biochemistry, Vanderbilt University School of Medicine, Nashville, TN 37232, USA. Electronic address: .
Ellis JD; Department of Biochemistry, Vanderbilt University School of Medicine, Nashville, TN 37232, USA.
Spielman CL; Department of Biochemistry, Vanderbilt University School of Medicine, Nashville, TN 37232, USA.
Bomber ML; Department of Biochemistry, Vanderbilt University School of Medicine, Nashville, TN 37232, USA.
Hiebert SW; Department of Biochemistry, Vanderbilt University School of Medicine, Nashville, TN 37232, USA; Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, TN 37232, USA. Electronic address: .
Pokaż więcej
Źródło :
Molecular cell [Mol Cell] 2021 Feb 04; Vol. 81 (3), pp. 530-545.e5. Date of Electronic Publication: 2020 Dec 30.
Typ publikacji :
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms :
Transcription, Genetic*
Core Binding Factor Alpha 2 Subunit/*metabolism
Hematopoietic Stem Cells/*metabolism
Leukemia, Myeloid, Acute/*metabolism
Neoplastic Stem Cells/*metabolism
Oncogene Proteins, Fusion/*metabolism
RNA, Neoplasm/*biosynthesis
RUNX1 Translocation Partner 1 Protein/*metabolism
Acetylation ; Binding Sites ; Binding, Competitive ; Cell Differentiation ; Cell Line, Tumor ; Cell Proliferation ; Cell Self Renewal ; Core Binding Factor Alpha 2 Subunit/genetics ; Fetal Blood/cytology ; Gene Expression Regulation, Leukemic ; Gene Regulatory Networks ; HEK293 Cells ; Hematopoietic Stem Cells/pathology ; Histones/metabolism ; Humans ; Leukemia, Myeloid, Acute/genetics ; Leukemia, Myeloid, Acute/pathology ; Neoplastic Stem Cells/pathology ; Oncogene Proteins, Fusion/genetics ; Protein Binding ; Proteolysis ; Proto-Oncogene Proteins/genetics ; Proto-Oncogene Proteins/metabolism ; RNA, Neoplasm/genetics ; RUNX1 Translocation Partner 1 Protein/genetics ; Repressor Proteins/genetics ; Repressor Proteins/metabolism ; Time Factors ; Transcriptome
Czasopismo naukowe
Tytuł :
How I diagnose and treat NPM1-mutated AML.
Autorzy :
Falini B; Institute of Hematology, Centro Ricerche Emato-Oncologiche, Ospedale S. Maria della Misericordia, University of Perugia, Perugia, Italy.
Brunetti L; Institute of Hematology, Centro Ricerche Emato-Oncologiche, Ospedale S. Maria della Misericordia, University of Perugia, Perugia, Italy.
Martelli MP; Institute of Hematology, Centro Ricerche Emato-Oncologiche, Ospedale S. Maria della Misericordia, University of Perugia, Perugia, Italy.
Pokaż więcej
Źródło :
Blood [Blood] 2021 Feb 04; Vol. 137 (5), pp. 589-599.
Typ publikacji :
Case Reports; Journal Article
MeSH Terms :
Practice Patterns, Physicians'*
Leukemia, Myeloid, Acute/*diagnosis
Leukemia, Myeloid, Acute/*therapy
Nuclear Proteins/*genetics
Oncogene Proteins, Fusion/*genetics
Age Factors ; Aged ; Algorithms ; Allografts ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Bone Marrow/pathology ; Bridged Bicyclo Compounds, Heterocyclic/administration & dosage ; Cell Lineage ; Clinical Trials as Topic ; Clonal Evolution ; Combined Modality Therapy ; Diagnosis, Differential ; Disease Management ; Female ; Gemtuzumab/administration & dosage ; Hematopoietic Stem Cell Transplantation ; Humans ; Leukemia, Myeloid, Acute/classification ; Leukemia, Myeloid, Acute/genetics ; Male ; Middle Aged ; Molecular Targeted Therapy ; Myelodysplastic Syndromes/chemically induced ; Myelodysplastic Syndromes/diagnosis ; Neoplastic Stem Cells/pathology ; Nuclear Proteins/antagonists & inhibitors ; Oncogene Proteins, Fusion/antagonists & inhibitors ; Patient Selection ; Remission Induction ; Risk Assessment ; Salvage Therapy ; Sulfonamides/administration & dosage ; fms-Like Tyrosine Kinase 3/genetics
Czasopismo naukowe
Tytuł :
Seeking commonalities in fusion proteins of NUP98.
Autorzy :
Slape CI; The University of Queensland Diamantina Institute, The University of Queensland, Woolloongabba, Queensland, Australia. .
Pokaż więcej
Źródło :
Nature structural & molecular biology [Nat Struct Mol Biol] 2021 Feb; Vol. 28 (2), pp. 123-124.
Typ publikacji :
Journal Article; Comment
MeSH Terms :
Nuclear Pore Complex Proteins*
Oncogene Proteins, Fusion*/metabolism
Czasopismo naukowe
Tytuł :
Opposing immune and genetic mechanisms shape oncogenic programs in synovial sarcoma.
Autorzy :
Jerby-Arnon L; Department of Genetics, Stanford University School of Medicine, Stanford, CA, USA.; Chan Zuckerberg Biohub, San Francisco, CA, USA.; Broad Institute of Harvard and MIT, Cambridge, MA, USA.; Klarman Cell Observatory, Broad Institute of Harvard and MIT, Cambridge, MA, USA.
Neftel C; Broad Institute of Harvard and MIT, Cambridge, MA, USA.; Klarman Cell Observatory, Broad Institute of Harvard and MIT, Cambridge, MA, USA.; Department of Pathology and Center for Cancer Research, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.; Institute of Pathology, Faculty of Biology and Medicine, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland.
Shore ME; Broad Institute of Harvard and MIT, Cambridge, MA, USA.; Klarman Cell Observatory, Broad Institute of Harvard and MIT, Cambridge, MA, USA.; Department of Pathology and Center for Cancer Research, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
Weisman HR; Broad Institute of Harvard and MIT, Cambridge, MA, USA.; Klarman Cell Observatory, Broad Institute of Harvard and MIT, Cambridge, MA, USA.; Department of Pathology and Center for Cancer Research, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
Mathewson ND; Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Immunology, Harvard Medical School, Boston, MA, USA.; Department of Neurology, Brigham and Women's Hospital, Boston, MA, USA.
McBride MJ; Department of Pediatric Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA.
Haas B; Broad Institute of Harvard and MIT, Cambridge, MA, USA.; Klarman Cell Observatory, Broad Institute of Harvard and MIT, Cambridge, MA, USA.
Izar B; Broad Institute of Harvard and MIT, Cambridge, MA, USA.; Columbia Center for Translational Immunology, New York, NY, USA.; Columbia University Medical Center, Division of Hematology and Oncology, New York, NY, USA.
Volorio A; Broad Institute of Harvard and MIT, Cambridge, MA, USA.; Department of Pathology and Center for Cancer Research, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
Boulay G; Broad Institute of Harvard and MIT, Cambridge, MA, USA.; Department of Pathology and Center for Cancer Research, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
Cironi L; Institute of Pathology, Faculty of Biology and Medicine, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland.
Richman AR; Broad Institute of Harvard and MIT, Cambridge, MA, USA.; Klarman Cell Observatory, Broad Institute of Harvard and MIT, Cambridge, MA, USA.; Department of Pathology and Center for Cancer Research, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
Broye LC; Institute of Pathology, Faculty of Biology and Medicine, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland.
Gurski JM; Massachusetts General Hospital Cancer Center, Boston, MA, USA.
Luo CC; Department of Pathology and Center for Cancer Research, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
Mylvaganam R; Department of Pathology and Center for Cancer Research, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
Nguyen L; Broad Institute of Harvard and MIT, Cambridge, MA, USA.
Mei S; Laboratory for Systems Pharmacology, Harvard Medical School, Boston, MA, USA.
Melms JC; Columbia Center for Translational Immunology, New York, NY, USA.; Columbia University Medical Center, Division of Hematology and Oncology, New York, NY, USA.
Georgescu C; Broad Institute of Harvard and MIT, Cambridge, MA, USA.
Cohen O; Broad Institute of Harvard and MIT, Cambridge, MA, USA.; Klarman Cell Observatory, Broad Institute of Harvard and MIT, Cambridge, MA, USA.; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA.
Buendia-Buendia JE; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA.
Segerstolpe A; Broad Institute of Harvard and MIT, Cambridge, MA, USA.
Sud M; Broad Institute of Harvard and MIT, Cambridge, MA, USA.
Cuoco MS; Broad Institute of Harvard and MIT, Cambridge, MA, USA.; Bioinformatics and Systems Biology Graduate Program, University of California, San Diego, La Jolla, CA, USA.
Labes D; Flow Cytometry Facility, Department of Biology and Medicine, University of Lausanne, Lausanne, Switzerland.
Gritsch S; Broad Institute of Harvard and MIT, Cambridge, MA, USA.; Klarman Cell Observatory, Broad Institute of Harvard and MIT, Cambridge, MA, USA.; Department of Pathology and Center for Cancer Research, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
Zollinger DR; NanoString Technologies, Seattle, WA, USA.
Ortogero N; NanoString Technologies, Seattle, WA, USA.
Beechem JM; NanoString Technologies, Seattle, WA, USA.
Petur Nielsen G; Department of Pathology and Center for Cancer Research, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
Chebib I; Massachusetts General Hospital Cancer Center, Boston, MA, USA.
Nguyen-Ngoc T; Department of Oncology, Centre Hospitalier Universitaire Vaudois, University of Lausanne, Lausanne, Switzerland.
Montemurro M; Department of Oncology, Centre Hospitalier Universitaire Vaudois, University of Lausanne, Lausanne, Switzerland.
Cote GM; Department of Medicine, Division of Hematology and Oncology, Massachusetts General Hospital, Boston, MA, USA.
Choy E; Department of Medicine, Division of Hematology and Oncology, Massachusetts General Hospital, Boston, MA, USA.
Letovanec I; Institute of Pathology, Faculty of Biology and Medicine, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland.
Cherix S; Department of Orthopedics, Faculty of Biology and Medicine, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland.
Wagle N; Broad Institute of Harvard and MIT, Cambridge, MA, USA.; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA.
Sorger PK; Laboratory for Systems Pharmacology, Harvard Medical School, Boston, MA, USA.
Haynes AB; Department of Surgery, Massachusetts General Hospital, Boston, MA, USA.
Mullen JT; Department of Surgery, Massachusetts General Hospital, Boston, MA, USA.
Stamenkovic I; Institute of Pathology, Faculty of Biology and Medicine, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland.
Rivera MN; Broad Institute of Harvard and MIT, Cambridge, MA, USA.; Department of Pathology and Center for Cancer Research, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
Kadoch C; Broad Institute of Harvard and MIT, Cambridge, MA, USA.; Department of Pediatric Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA.
Wucherpfennig KW; Broad Institute of Harvard and MIT, Cambridge, MA, USA.; Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Immunology, Harvard Medical School, Boston, MA, USA.
Rozenblatt-Rosen O; Broad Institute of Harvard and MIT, Cambridge, MA, USA.; Klarman Cell Observatory, Broad Institute of Harvard and MIT, Cambridge, MA, USA.; Genentech, South San Francisco, CA, USA.
Suvà ML; Broad Institute of Harvard and MIT, Cambridge, MA, USA. .; Klarman Cell Observatory, Broad Institute of Harvard and MIT, Cambridge, MA, USA. .; Department of Pathology and Center for Cancer Research, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA. .
Riggi N; Department of Pathology and Center for Cancer Research, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA. .; Institute of Pathology, Faculty of Biology and Medicine, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland. .
Regev A; Broad Institute of Harvard and MIT, Cambridge, MA, USA. .; Klarman Cell Observatory, Broad Institute of Harvard and MIT, Cambridge, MA, USA. .; Howard Hughes Medical Institute, Koch Institute for Integrative Cancer Research, Department of Biology, MIT, Cambridge, MA, USA. .; Genentech, South San Francisco, CA, USA. .
Pokaż więcej
Źródło :
Nature medicine [Nat Med] 2021 Feb; Vol. 27 (2), pp. 289-300. Date of Electronic Publication: 2021 Jan 25.
Typ publikacji :
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms :
Molecular Targeted Therapy*
Carcinogenesis/*genetics
Oncogene Proteins, Fusion/*genetics
Sarcoma, Synovial/*drug therapy
Cell Line, Tumor ; Cyclin-Dependent Kinase 4/antagonists & inhibitors ; Histone Deacetylase Inhibitors/therapeutic use ; Histone Deacetylases/genetics ; Histone Deacetylases/therapeutic use ; Humans ; Oncogene Proteins, Fusion/antagonists & inhibitors ; Oncogenes/genetics ; RNA-Seq ; Sarcoma, Synovial/genetics ; Sarcoma, Synovial/pathology ; Single-Cell Analysis
Czasopismo naukowe
Tytuł :
Identification of a novel TNRC18-RARA fusion in acute promyelocytic leukemia lacking t(15;17)(q24;q12)/PML-RARA.
Autorzy :
Wang Z; National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, the First Affiliated Hospital of Soochow University, Soochow University, Suzhou, P.R. China.; Suzhou Jsuniwell Medical Laboratory, Suzhou, P.R. China.
Wen L; National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, the First Affiliated Hospital of Soochow University, Soochow University, Suzhou, P.R. China.
Zhang L; National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, the First Affiliated Hospital of Soochow University, Soochow University, Suzhou, P.R. China.
Xu X; National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, the First Affiliated Hospital of Soochow University, Soochow University, Suzhou, P.R. China.
Chen X; National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, the First Affiliated Hospital of Soochow University, Soochow University, Suzhou, P.R. China.
Yao L; National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, the First Affiliated Hospital of Soochow University, Soochow University, Suzhou, P.R. China.
Wang M; National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, the First Affiliated Hospital of Soochow University, Soochow University, Suzhou, P.R. China.
Shen Z; National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, the First Affiliated Hospital of Soochow University, Soochow University, Suzhou, P.R. China.
Mo G; Department of Hematology, The First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning, P.R. China.
Wang Y; Department of Hematology, The First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning, P.R. China.
Zhao D; Department of Hematology, The First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning, P.R. China.
Cai W; Department of Hematology, The First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning, P.R. China.
Shen J; Department of Hematology, The First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning, P.R. China.
Chi X; Dalian Municipal Friendship Hospital, Dalian, Liaoning, P.R. China.
Xu Y; National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, the First Affiliated Hospital of Soochow University, Soochow University, Suzhou, P.R. China.
Zeng Z; National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, the First Affiliated Hospital of Soochow University, Soochow University, Suzhou, P.R. China.
Pan J; National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, the First Affiliated Hospital of Soochow University, Soochow University, Suzhou, P.R. China.
Ruan C; National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, the First Affiliated Hospital of Soochow University, Soochow University, Suzhou, P.R. China.; Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, P.R. China.
Wu D; National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, the First Affiliated Hospital of Soochow University, Soochow University, Suzhou, P.R. China.; Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, P.R. China.
Jia Z; Department of Hematology, The First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning, P.R. China.
Chen S; National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, the First Affiliated Hospital of Soochow University, Soochow University, Suzhou, P.R. China.; Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, P.R. China.
Pokaż więcej
Źródło :
Molecular carcinogenesis [Mol Carcinog] 2021 Feb; Vol. 60 (2). Date of Electronic Publication: 2021 Jan 11.
Typ publikacji :
Case Reports; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Translocation, Genetic*
Chromosomes, Human, Pair 15/*genetics
Chromosomes, Human, Pair 17/*genetics
Intracellular Signaling Peptides and Proteins/*genetics
Leukemia, Promyelocytic, Acute/*genetics
Oncogene Proteins, Fusion/*genetics
Retinoic Acid Receptor alpha/*genetics
Gene Expression Regulation, Leukemic ; Humans ; In Situ Hybridization, Fluorescence ; Intracellular Signaling Peptides and Proteins/metabolism ; Leukemia, Promyelocytic, Acute/metabolism ; Leukemia, Promyelocytic, Acute/pathology ; Male ; Middle Aged ; Oncogene Proteins, Fusion/metabolism ; Retinoic Acid Receptor alpha/metabolism
Czasopismo naukowe
Tytuł :
The RUNX1/RUNX1T1 network: translating insights into therapeutic options.
Autorzy :
Swart LE; Princess Maxima Center for Pediatric Oncology, Utrecht, The Netherlands.
Heidenreich O; Princess Maxima Center for Pediatric Oncology, Utrecht, The Netherlands. Electronic address: .
Pokaż więcej
Źródło :
Experimental hematology [Exp Hematol] 2021 Feb; Vol. 94, pp. 1-10. Date of Electronic Publication: 2020 Nov 17.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't; Review
MeSH Terms :
Gene Expression Regulation, Leukemic*
Core Binding Factor Alpha 2 Subunit/*genetics
Leukemia, Myeloid, Acute/*genetics
Oncogene Proteins, Fusion/*genetics
RUNX1 Translocation Partner 1 Protein/*genetics
Animals ; Cell Cycle ; Core Binding Factor Alpha 2 Subunit/metabolism ; Gene Regulatory Networks ; Humans ; Leukemia, Myeloid, Acute/metabolism ; Leukemia, Myeloid, Acute/pathology ; Leukemia, Myeloid, Acute/therapy ; Oncogene Proteins, Fusion/metabolism ; Protein Interaction Maps ; RUNX1 Translocation Partner 1 Protein/metabolism ; Transcriptional Activation
Czasopismo naukowe
Tytuł :
RUNX1/RUNX1T1 mediates alternative splicing and reorganises the transcriptional landscape in leukemia.
Autorzy :
Grinev VV; Department of Genetics, Faculty of Biology, Belarusian State University, 220030, Minsk, Republic of Belarus. .
Barneh F; Princess Maxima Center for Pediatric Oncology, 3584, CS, Utrecht, The Netherlands.
Ilyushonak IM; Department of Genetics, Faculty of Biology, Belarusian State University, 220030, Minsk, Republic of Belarus.
Nakjang S; Wolfson Childhood Cancer Research Centre, Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, NE1 7RU, UK.
Smink J; Princess Maxima Center for Pediatric Oncology, 3584, CS, Utrecht, The Netherlands.
van Oort A; Princess Maxima Center for Pediatric Oncology, 3584, CS, Utrecht, The Netherlands.
Clough R; Wolfson Childhood Cancer Research Centre, Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, NE1 7RU, UK.
Seyani M; Wolfson Childhood Cancer Research Centre, Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, NE1 7RU, UK.
McNeill H; Wolfson Childhood Cancer Research Centre, Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, NE1 7RU, UK.
Reza M; Wolfson Childhood Cancer Research Centre, Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, NE1 7RU, UK.
Martinez-Soria N; Wolfson Childhood Cancer Research Centre, Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, NE1 7RU, UK.
Assi SA; Institute of Cancer and Genomic Sciences, College of Medical and Dental Sciences, University of Birmingham, Birmingham, B15 2TT, UK.
Ramanouskaya TV; Department of Genetics, Faculty of Biology, Belarusian State University, 220030, Minsk, Republic of Belarus.
Bonifer C; Institute of Cancer and Genomic Sciences, College of Medical and Dental Sciences, University of Birmingham, Birmingham, B15 2TT, UK.
Heidenreich O; Princess Maxima Center for Pediatric Oncology, 3584, CS, Utrecht, The Netherlands. .; Wolfson Childhood Cancer Research Centre, Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, NE1 7RU, UK. .; Newcastle University Centre for Cancer, Newcastle University, Newcastle upon Tyne, NE1 7RU, UK. .
Pokaż więcej
Źródło :
Nature communications [Nat Commun] 2021 Jan 22; Vol. 12 (1), pp. 520. Date of Electronic Publication: 2021 Jan 22.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Alternative Splicing*
Gene Expression Regulation, Leukemic*
Core Binding Factor Alpha 2 Subunit/*genetics
Leukemia, Myeloid/*genetics
Oncogene Proteins, Fusion/*genetics
RUNX1 Translocation Partner 1 Protein/*genetics
Acute Disease ; Cell Line, Tumor ; Core Binding Factor Alpha 2 Subunit/metabolism ; Gene Expression Profiling/methods ; Humans ; Leukemia, Myeloid/pathology ; Models, Genetic ; Oncogene Proteins, Fusion/metabolism ; RNA Interference ; RNA Isoforms/genetics ; RNA Isoforms/metabolism ; RUNX1 Translocation Partner 1 Protein/metabolism ; Transcription Initiation Site
Czasopismo naukowe
Tytuł :
Interaction between SNAI2 and MYOD enhances oncogenesis and suppresses differentiation in Fusion Negative Rhabdomyosarcoma.
Autorzy :
Pomella S; Department of Pediatric Hematology and Oncology, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.; Genetics Branch, NCI, NIH, Bethesda, MD, USA.
Sreenivas P; Greehey Children's Cancer Research Institute, Department of Molecular Medicine, University of Texas Health Sciences Center, San Antonio, Texas, USA.
Gryder BE; Genetics Branch, NCI, NIH, Bethesda, MD, USA.
Wang L; Greehey Children's Cancer Research Institute, Department of Molecular Medicine, University of Texas Health Sciences Center, San Antonio, Texas, USA.
Milewski D; Genetics Branch, NCI, NIH, Bethesda, MD, USA.
Cassandri M; Department of Pediatric Hematology and Oncology, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
Baxi K; Greehey Children's Cancer Research Institute, Department of Molecular Medicine, University of Texas Health Sciences Center, San Antonio, Texas, USA.
Hensch NR; Greehey Children's Cancer Research Institute, Department of Molecular Medicine, University of Texas Health Sciences Center, San Antonio, Texas, USA.
Carcarino E; Department of Pediatric Hematology and Oncology, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
Song Y; Genetics Branch, NCI, NIH, Bethesda, MD, USA.
Chou HC; Genetics Branch, NCI, NIH, Bethesda, MD, USA.
Yohe ME; Genetics Branch, NCI, NIH, Bethesda, MD, USA.; Pediatric Oncology Branch, NCI, NIH, Bethesda, MD, USA.
Stanton BZ; Center for Childhood Cancer and Blood Diseases, Abigail Wexner Research Institute at Nationwide Children's Hospital, The Ohio State University, Columbus, OH, 43205, USA.
Amadio B; SAFU Laboratory, Translational Research Area, Regina Elena National Cancer Institute, Rome, Italy.
Caruana I; Department of Pediatric Hematology and Oncology, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
De Stefanis C; Histology-Core Facility, Bambino Gesu' Children's Hospital, IRCCS, Rome, Italy.
De Vito R; Department of Pathology Unit, Department of Laboratories, Bambino Gesu' Children's Hospital, IRCCS, Rome, Italy.
Locatelli F; Department of Pediatric Hematology and Oncology, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.; Departmentof Pediatrics, Sapienza University of Rome, Rome, Italy.
Chen Y; Greehey Children's Cancer Research Institute, Department of Molecular Medicine, University of Texas Health Sciences Center, San Antonio, Texas, USA.
Chen EY; Department of Pathology, University of Washington, Seattle, WA, 98195, USA.
Houghton P; Greehey Children's Cancer Research Institute, Department of Molecular Medicine, University of Texas Health Sciences Center, San Antonio, Texas, USA.
Khan J; Genetics Branch, NCI, NIH, Bethesda, MD, USA. .
Rota R; Department of Pediatric Hematology and Oncology, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy. .
Ignatius MS; Greehey Children's Cancer Research Institute, Department of Molecular Medicine, University of Texas Health Sciences Center, San Antonio, Texas, USA. .
Pokaż więcej
Źródło :
Nature communications [Nat Commun] 2021 Jan 08; Vol. 12 (1), pp. 192. Date of Electronic Publication: 2021 Jan 08.
Typ publikacji :
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
MeSH Terms :
Cell Differentiation*/genetics
Carcinogenesis/*metabolism
MyoD Protein/*metabolism
Oncogene Proteins, Fusion/*metabolism
Rhabdomyosarcoma/*genetics
Rhabdomyosarcoma/*metabolism
Snail Family Transcription Factors/*metabolism
Animals ; Carcinogenesis/genetics ; Cell Line, Tumor ; Cyclin-Dependent Kinase Inhibitor p21/metabolism ; Female ; Gene Expression Regulation, Neoplastic ; Gene Knockdown Techniques ; Heterografts ; Humans ; MEF2 Transcription Factors/metabolism ; Male ; Mice ; Mice, SCID ; Muscle Development/genetics ; MyoD Protein/genetics ; Myogenin/metabolism ; Oncogene Proteins, Fusion/genetics ; Oncogenes ; Rhabdomyosarcoma/pathology ; Rhabdomyosarcoma, Alveolar/genetics ; Rhabdomyosarcoma, Embryonal/genetics ; Snail Family Transcription Factors/genetics ; Transcriptome
Czasopismo naukowe
Tytuł :
The effect of metformin in EML 4 -ALK+ lung cancer alone and in combination with crizotinib in cell and rodent models.
Autorzy :
Bland AR; Department of Pharmacology and Toxicology, School of Biomedical Sciences, University of Otago, Dunedin, New Zealand.
Shrestha N; Department of Pharmacology and Toxicology, School of Biomedical Sciences, University of Otago, Dunedin, New Zealand.
Bower RL; Department of Pharmacology and Toxicology, School of Biomedical Sciences, University of Otago, Dunedin, New Zealand.
Rosengren RJ; Department of Pharmacology and Toxicology, School of Biomedical Sciences, University of Otago, Dunedin, New Zealand.
Ashton JC; Department of Pharmacology and Toxicology, School of Biomedical Sciences, University of Otago, Dunedin, New Zealand. Electronic address: .
Pokaż więcej
Źródło :
Biochemical pharmacology [Biochem Pharmacol] 2021 Jan; Vol. 183, pp. 114345. Date of Electronic Publication: 2020 Nov 21.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Disease Models, Animal*
Oncogene Proteins, Fusion*/genetics
Antineoplastic Agents/*administration & dosage
Crizotinib/*administration & dosage
Lung Neoplasms/*drug therapy
Metformin/*administration & dosage
A549 Cells ; Animals ; Antineoplastic Combined Chemotherapy Protocols/administration & dosage ; Cell Survival/drug effects ; Cell Survival/physiology ; Dose-Response Relationship, Drug ; Humans ; Lung Neoplasms/genetics ; Male ; Mice ; Mice, Inbred BALB C ; Mice, Nude ; Rodentia
Czasopismo naukowe
Tytuł :
Covalent inhibition of NSD1 histone methyltransferase.
Autorzy :
Huang H; Department of Pathology, University of Michigan, Ann Arbor, MI, USA.
Howard CA; Department of Pathology, University of Michigan, Ann Arbor, MI, USA.; Program in Chemical Biology, University of Michigan, Ann Arbor, MI, USA.
Zari S; Department of Pathology, University of Michigan, Ann Arbor, MI, USA.
Cho HJ; Department of Pathology, University of Michigan, Ann Arbor, MI, USA.
Shukla S; Department of Pathology, University of Michigan, Ann Arbor, MI, USA.
Li H; Department of Pathology, University of Michigan, Ann Arbor, MI, USA.; Program in Chemical Biology, University of Michigan, Ann Arbor, MI, USA.
Ndoj J; Department of Pathology, University of Michigan, Ann Arbor, MI, USA.
González-Alonso P; Department of Pathology, University of Michigan, Ann Arbor, MI, USA.
Nikolaidis C; Department of Pathology, University of Michigan, Ann Arbor, MI, USA.
Abbott J; Department of Pathology, University of Michigan, Ann Arbor, MI, USA.
Rogawski DS; Department of Pathology, University of Michigan, Ann Arbor, MI, USA.
Potopnyk MA; Department of Pathology, University of Michigan, Ann Arbor, MI, USA.
Kempinska K; Department of Pathology, University of Michigan, Ann Arbor, MI, USA.
Miao H; Department of Pathology, University of Michigan, Ann Arbor, MI, USA.
Purohit T; Department of Pathology, University of Michigan, Ann Arbor, MI, USA.
Henderson A; Life Sciences Institute, University of Michigan, Ann Arbor, MI, USA.
Mapp A; Program in Chemical Biology, University of Michigan, Ann Arbor, MI, USA.; Life Sciences Institute, University of Michigan, Ann Arbor, MI, USA.
Sulis ML; Department of Pediatric Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Ferrando A; Institute for Cancer Genetics, Columbia University, New York, NY, USA.; Department of Systems Biology, Columbia University, New York, NY, USA.; Department of Pathology & Cell Biology, Columbia University, New York, NY, USA.; Department of Pediatrics, Columbia University, New York, NY, USA.
Grembecka J; Department of Pathology, University of Michigan, Ann Arbor, MI, USA. .; Program in Chemical Biology, University of Michigan, Ann Arbor, MI, USA. .
Cierpicki T; Department of Pathology, University of Michigan, Ann Arbor, MI, USA. .; Program in Chemical Biology, University of Michigan, Ann Arbor, MI, USA. .; Department of Biophysics, University of Michigan, Ann Arbor, MI, USA. .
Pokaż więcej
Źródło :
Nature chemical biology [Nat Chem Biol] 2020 Dec; Vol. 16 (12), pp. 1403-1410. Date of Electronic Publication: 2020 Aug 31.
Typ publikacji :
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
MeSH Terms :
Gene Expression Regulation, Leukemic*
Antineoplastic Agents/*pharmacology
Enzyme Inhibitors/*pharmacology
Histone-Lysine N-Methyltransferase/*antagonists & inhibitors
Leukocytes/*drug effects
Nuclear Pore Complex Proteins/*genetics
Oncogene Proteins, Fusion/*antagonists & inhibitors
Antineoplastic Agents/chemical synthesis ; Binding Sites ; Enzyme Inhibitors/chemical synthesis ; Histone-Lysine N-Methyltransferase/genetics ; Histone-Lysine N-Methyltransferase/metabolism ; Homeodomain Proteins/genetics ; Homeodomain Proteins/metabolism ; Humans ; Kinetics ; Leukemia/drug therapy ; Leukemia/enzymology ; Leukemia/genetics ; Leukemia/pathology ; Leukocytes/enzymology ; Leukocytes/pathology ; Models, Molecular ; Myeloid Ecotropic Viral Integration Site 1 Protein/genetics ; Myeloid Ecotropic Viral Integration Site 1 Protein/metabolism ; Nuclear Pore Complex Proteins/metabolism ; Oncogene Proteins, Fusion/genetics ; Oncogene Proteins, Fusion/metabolism ; Protein Binding ; Protein Conformation, alpha-Helical ; Protein Conformation, beta-Strand ; Protein Interaction Domains and Motifs ; Signal Transduction ; Substrate Specificity ; Tumor Cells, Cultured
Czasopismo naukowe
Tytuł :
Detection of EP300-ZNF384 fusion in patients with acute lymphoblastic leukemia using RNA fusion gene panel sequencing.
Autorzy :
Jing Y; Department of Hematology, Chinese People's Liberation Army General Hospital, 100853, Beijing, China.
Li YF; Department of Hematology, Chinese People's Liberation Army General Hospital, 100853, Beijing, China.
Wan H; Beijing USCI Medical Laboratory, Beijing, 100195, China.
Liu DH; Department of Hematology, Chinese People's Liberation Army General Hospital, 100853, Beijing, China. .
Pokaż więcej
Źródło :
Annals of hematology [Ann Hematol] 2020 Nov; Vol. 99 (11), pp. 2611-2617. Date of Electronic Publication: 2020 Sep 26.
Typ publikacji :
Clinical Trial; Journal Article
MeSH Terms :
E1A-Associated p300 Protein*/genetics
E1A-Associated p300 Protein*/metabolism
Oncogene Proteins, Fusion*/genetics
Oncogene Proteins, Fusion*/metabolism
Precursor Cell Lymphoblastic Leukemia-Lymphoma*/diagnosis
Precursor Cell Lymphoblastic Leukemia-Lymphoma*/drug therapy
Precursor Cell Lymphoblastic Leukemia-Lymphoma*/genetics
Precursor Cell Lymphoblastic Leukemia-Lymphoma*/metabolism
RNA, Neoplasm*/genetics
RNA, Neoplasm*/metabolism
Sequence Analysis, RNA*
Trans-Activators*/genetics
Trans-Activators*/metabolism
Adult ; Cohort Studies ; Female ; Humans ; Male
Czasopismo naukowe
Tytuł :
Primary central nervous system erythroid sarcoma with NFIA-CBFA2T3 translocation: A rare but distinct clinicopathologic entity.
Autorzy :
Linnik Y; Department of Pathology, Microbiology, and Immunology, Division of Hematopathology, Vanderbilt University Medical Center, Nashville, Tennessee.
Pastakia D; Department of Pediatrics, Division of Pediatric Hematology and Oncology, Monroe Carell Jr. Children's Hospital at Vanderbilt, Nashville, Tennessee.
Dryden I; Department of Pathology, Microbiology, and Immunology, Division of Neuropathology, Vanderbilt University Medical Center, Nashville, Tennessee.
Head DR; Department of Pathology, Microbiology, and Immunology, Division of Hematopathology, Vanderbilt University Medical Center, Nashville, Tennessee.
Mason EF; Department of Pathology, Microbiology, and Immunology, Division of Hematopathology, Vanderbilt University Medical Center, Nashville, Tennessee.
Pokaż więcej
Źródło :
American journal of hematology [Am J Hematol] 2020 Nov; Vol. 95 (11), pp. E299-E301. Date of Electronic Publication: 2020 Aug 17.
Typ publikacji :
Case Reports; Letter
MeSH Terms :
Brain Neoplasms*/diagnostic imaging
Brain Neoplasms*/genetics
NFI Transcription Factors*/genetics
NFI Transcription Factors*/metabolism
Oncogene Proteins, Fusion*/genetics
Oncogene Proteins, Fusion*/metabolism
Repressor Proteins*/genetics
Repressor Proteins*/metabolism
Sarcoma*/diagnostic imaging
Sarcoma*/genetics
Sarcoma*/metabolism
Translocation, Genetic*
Child, Preschool ; Humans ; Male
Raport
Tytuł :
Epidemiology, clinical picture and long-term outcomes of FIP1L1-PDGFRA-positive myeloid neoplasm with eosinophilia: Data from 151 patients.
Autorzy :
Rohmer J; National Reference Center for Hypereosinophilic syndromes (CEREO), Suresnes, France.; Department of Internal Medicine, Hôpital Foch, Suresnes, France.
Couteau-Chardon A; National Reference Center for Hypereosinophilic syndromes (CEREO), Suresnes, France.; Department of Intensive Care medicine, Centre Hospitalier Annecy Genevois, Saint-Julien-en-Genevois, France.
Trichereau J; National Reference Center for Hypereosinophilic syndromes (CEREO), Suresnes, France.; Clinical Research Department, Hôpital Foch, Suresnes, France.
Panel K; National Reference Center for Hypereosinophilic syndromes (CEREO), Suresnes, France.; Clinical Research Department, Hôpital Foch, Suresnes, France.
Gesquiere C; National Reference Center for Hypereosinophilic syndromes (CEREO), Suresnes, France.
Ben Abdelali R; Pole Hématologie et Oncologie, Laboratoire CERBA, Saint-Ouen-l'Aumône, France.
Bidet A; Laboratory of Hematology, CHU de Bordeaux, Pessac, France.
Bladé JS; Department of Oncology, Sainte-Anne Military Teaching Hospital, Toulon, France.
Cayuela JM; Laboratory of Hematology, Saint-Louis Hospital, University of Paris, Paris, France.
Cony-Makhoul P; National Reference Center for Hypereosinophilic syndromes (CEREO), Suresnes, France.; Hematology Department, CH Annecy Genevois, Annecy, France.
Cottin V; National Coordinating Reference Center for Rare Pulmonary Diseases, Louis Pradel Hospital, Lyon, France.; Hospices Civils de Lyon, UMR754, University Claude Bernard Lyon 1, Lyon, France.
Delabesse E; Laboratory of Hematology, Institut Universitaire du Cancer de Toulouse Oncopole, CHU de Toulouse, Toulouse, France.
Ebbo M; National Reference Center for Hypereosinophilic syndromes (CEREO), Suresnes, France.; Aix Marseille University, Department of Internal Medicine, Hôpital de la Timone, AP-HM, CNRS, INSERM, CIML, Marseille, France.
Fain O; Department of Internal Medicine, CHU Saint Antoine, Paris, France.
Flandrin P; Laboratory of Hematology, Hôpital Nord, CHU de Saint-Étienne, Saint-Étienne, France.
Galicier L; Department of Clinical Immunology, Saint Louis hospital, Paris, France.
Godon C; Laboratoire de cytogénétique hématologique, CHU de Nantes, Nantes, France.
Grardel N; Laboratory of Hematology, CHU de Lille, Lille, France.
Guffroy A; National Reference Center for Hypereosinophilic syndromes (CEREO), Suresnes, France.; Department of Clinical Immunology and Internal Medicine, National Reference Center for Systemic Autoimmune Diseases (RESO), Tertiary Center for Primary Immunodeficiency, Strasbourg University Hospital, Strasbourg, France.
Hamidou M; National Reference Center for Hypereosinophilic syndromes (CEREO), Suresnes, France.; Department of Internal Medicine, CHU de Nantes, Nantes, France.
Hunault M; CRCINA CHU d'Angers, Angers, France.
Lengline E; Department of Hematology, Saint Louis hospital, Paris, France.
Lhomme F; Department of Hematology, CHU Pontchaillou, Rennes, France.
Lhermitte L; University of Paris, Institut National de Recherche Médicale U1151, Laboratory of Onco-Hematology, Hôpital Necker Enfants-Malades, Paris, France.
Machelart I; National Reference Center for Hypereosinophilic syndromes (CEREO), Suresnes, France.; Department of Internal Medicine, CHU de Bordeaux, Bordeaux, France.
Mauvieux L; Université de Strasbourg, INSERM U1113 Interface de Recherche Fondamentale et Appliquée en Cancérologie, Laboratoire d'hématologie du CHRU Strasbourg, Faculté de Médecine de Strasbourg, Strasbourg, France.
Mohr C; Service d'Hématologie Oncologie, CHU, Groupe Hospitalier Sud Réunion, Saint Pierre, Reunion, France.
Mozicconacci MJ; Institut Paoli-Calmettes, Centre de Recherche en Cancérologie de Marseille, Biopathologie, Marseille, France.
Naguib D; Laboratory of Hematology, CHU Caen, Caen, France.
Nicolini FE; Department of Hematology, INSERM U 1052, CRCL, Centre Léon Bérard, Lyon, France.
Rey J; Department of Hematology, Institut Paoli-Calmettes, Marseille, France.
Rousselot P; Hematology Department, Versailles André Mignot Hospital, University Paris-Saclay, Le Chesnay, France.
Tavitian S; Service d'Hématologie, Institut Universitaire du Cancer de Toulouse-Oncopole, Centre Hospitalier Universitaire de Toulouse, Toulouse, France.
Terriou L; National Reference Center for Hypereosinophilic syndromes (CEREO), Suresnes, France.; Université de Lille, CHU Lille, Département de Médecine Interne et Immunologie Clinique, Centre de Référence des Maladies Auto-immunes Systémiques Rares du Nord et Nord-Ouest de France (CeRAINO), Lille, France.
Lefèvre G; National Reference Center for Hypereosinophilic syndromes (CEREO), Suresnes, France.; Université de Lille, CHU Lille, Département de Médecine Interne et Immunologie Clinique, Centre de Référence des Maladies Auto-immunes Systémiques Rares du Nord et Nord-Ouest de France (CeRAINO), Lille, France.
Preudhomme C; Laboratory of Hematology, CHU de Lille, Lille, France.
Kahn JE; National Reference Center for Hypereosinophilic syndromes (CEREO), Suresnes, France.; Université Paris-Saclay, Department of Internal Medicine, Ambroise Paré hospital, Boulogne Billancourt Cedex, France.
Groh M; National Reference Center for Hypereosinophilic syndromes (CEREO), Suresnes, France.; Department of Internal Medicine, Hôpital Foch, Suresnes, France.
Pokaż więcej
Corporate Authors :
CEREO and GBMHM collaborators
Źródło :
American journal of hematology [Am J Hematol] 2020 Nov; Vol. 95 (11), pp. 1314-1323. Date of Electronic Publication: 2020 Sep 19.
Typ publikacji :
Clinical Trial; Journal Article; Multicenter Study
MeSH Terms :
Eosinophilia*/blood
Eosinophilia*/drug therapy
Eosinophilia*/genetics
Eosinophilia*/mortality
Hematologic Neoplasms*/blood
Hematologic Neoplasms*/drug therapy
Hematologic Neoplasms*/genetics
Hematologic Neoplasms*/mortality
Myeloproliferative Disorders*/blood
Myeloproliferative Disorders*/drug therapy
Myeloproliferative Disorders*/genetics
Myeloproliferative Disorders*/mortality
Oncogene Proteins, Fusion*/blood
Oncogene Proteins, Fusion*/genetics
Receptor, Platelet-Derived Growth Factor alpha*/blood
Receptor, Platelet-Derived Growth Factor alpha*/genetics
mRNA Cleavage and Polyadenylation Factors*/blood
mRNA Cleavage and Polyadenylation Factors*/genetics
Adrenal Cortex Hormones/*administration & dosage
Adult ; Disease-Free Survival ; Female ; France/epidemiology ; Humans ; Incidence ; Male ; Middle Aged ; Retrospective Studies ; Survival Rate ; Tryptases/blood ; Vitamin B 12/blood
Czasopismo naukowe
Tytuł :
High prevalence of MEF2D fusion in human B-cell precursor acute lymphoblastic leukemia cell lines.
Autorzy :
Akahane K; Department of Pediatrics, School of Medicine, University of Yamanashi, Chuo, Japan.
Yasuda T; Clinical Research Center, National Hospital Organization Nagoya Medical Center, Nagoya, Japan.
Tsuzuki S; Department of Biochemistry, Aichi Medical University, Nagakute, Japan.
Hayakawa F; Department of Pathophysiological Laboratory Sciences, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Kiyokawa N; Department of Pediatric Hematology and Oncology Research, National Research Institute for Child Health and Development, Tokyo, Japan.
Somazu S; Department of Pediatrics, School of Medicine, University of Yamanashi, Chuo, Japan.
Watanabe A; Department of Pediatrics, School of Medicine, University of Yamanashi, Chuo, Japan.
Kagami K; Department of Pediatrics, School of Medicine, University of Yamanashi, Chuo, Japan.
Abe M; Department of Pediatrics, School of Medicine, University of Yamanashi, Chuo, Japan.
Harama D; Department of Pediatrics, School of Medicine, University of Yamanashi, Chuo, Japan.
Goi K; Department of Pediatrics, School of Medicine, University of Yamanashi, Chuo, Japan.
Kawazu M; Division of Cellular Signaling, National Cancer Center Research Institute, Tokyo, Japan.
Kojima S; Division of Cellular Signaling, National Cancer Center Research Institute, Tokyo, Japan.
Imamura T; Department of Pediatrics, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Goto H; Department of Hematology/Oncology, Kanagawa Children's Medical Center, Yokohama, Japan.
Iwamoto S; Department of Pediatrics, Mie University Graduate School of Medicine, Tsu, Japan.
Minegishi M; Japanese Red Cross Miyagi Blood Center, Sendai, Japan.
Abe M; Professor Emeritus, Fukushima Medical University, Fukushima, Japan.
Hojo H; Department of Clinical Medicine Diagnostic Pathology, Aizu Medical Center, Fukushima Medical University, Aizuwakamatsu, Japan.
Inaba T; Department of Molecular Oncology and Leukemia Program Project, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan.
Mano H; Division of Cellular Signaling, National Cancer Center Research Institute, Tokyo, Japan.
Sugita K; Department of Pediatrics, School of Medicine, University of Yamanashi, Chuo, Japan.
Inukai T; Department of Pediatrics, School of Medicine, University of Yamanashi, Chuo, Japan.
Pokaż więcej
Źródło :
Hematological oncology [Hematol Oncol] 2020 Oct; Vol. 38 (4), pp. 614-617. Date of Electronic Publication: 2020 Jun 24.
Typ publikacji :
Letter
MeSH Terms :
Oncogene Proteins, Fusion*/genetics
Oncogene Proteins, Fusion*/metabolism
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma*/genetics
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma*/metabolism
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma*/pathology
Cell Line, Tumor ; Humans ; MEF2 Transcription Factors/genetics ; MEF2 Transcription Factors/metabolism
Opinia redakcyjna
Tytuł :
PML-RARA monitoring in newly diagnosed acute promyelocytic leukemia treated with an entirely oral chemotherapy-free postremission approach: A multiple institution experience.
Autorzy :
Lou Y; Department of Hematology, Leukemia Center, The First Affiliated Hospital of Zhejiang University, College of Medicine, Hangzhou, China.; Zhejiang University, Key Laboratory of Hematopoietic Malignancies in Zhejiang Province, Hangzhou, China.
Lu Y; Department of Hematology, The Ningbo Yinzhou People's Hospital, Ningbo, China.
Ye X; Department of Hematology, Leukemia Center, The First Affiliated Hospital of Zhejiang University, College of Medicine, Hangzhou, China.; Department of Hematology, The Fourth Affiliated Hospital of Zhejiang University, College of Medicine, Yiwu, China.
Wang Y; Department of Hematology, Leukemia Center, The First Affiliated Hospital of Zhejiang University, College of Medicine, Hangzhou, China.
Ma Y; Department of Hematology, Leukemia Center, The First Affiliated Hospital of Zhejiang University, College of Medicine, Hangzhou, China.
Fan C; Department of Hematology, Shulan Hospital, Hangzhou, China.
Jiang H; Department of Hematology, Tongde Hospital of Zhejiang Province, Hangzhou, China.
Jin J; Department of Hematology, Leukemia Center, The First Affiliated Hospital of Zhejiang University, College of Medicine, Hangzhou, China.; Zhejiang University, Key Laboratory of Hematopoietic Malignancies in Zhejiang Province, Hangzhou, China.
Pokaż więcej
Źródło :
Hematological oncology [Hematol Oncol] 2020 Oct; Vol. 38 (4), pp. 618-621. Date of Electronic Publication: 2020 Jul 29.
Typ publikacji :
Clinical Trial; Letter; Multicenter Study
MeSH Terms :
Leukemia, Promyelocytic, Acute*/blood
Leukemia, Promyelocytic, Acute*/diagnosis
Leukemia, Promyelocytic, Acute*/drug therapy
Leukemia, Promyelocytic, Acute*/genetics
Oncogene Proteins, Fusion*/blood
Oncogene Proteins, Fusion*/genetics
Antineoplastic Combined Chemotherapy Protocols/*administration & dosage
Administration, Oral ; Adolescent ; Adult ; Aged ; Aged, 80 and over ; Arsenicals/administration & dosage ; Female ; Follow-Up Studies ; Humans ; Male ; Middle Aged ; Retrospective Studies ; Tretinoin/administration & dosage
Raport
Tytuł :
Reciprocal ATP5L-KMT2A gene fusion in a paediatric B lymphoblastic leukaemia/lymphoma (B-ALL) patient.
Autorzy :
Gestrich CK; Department of Pathology, University Hospitals Cleveland Medical Center/Case Western Reserve University, Cleveland, OH, USA.
Sadri N; Department of Pathology, University Hospitals Cleveland Medical Center/Case Western Reserve University, Cleveland, OH, USA.
Sinno MG; Department of Pediatrics, Division of Pediatric Hematology/Oncology, University Hospitals Cleveland Medical Center, Rainbow Babies and Children's Hospital/Case Western Reserve University, Cleveland, OH, USA.
Pateva I; Department of Pediatrics, Division of Pediatric Hematology/Oncology, University Hospitals Cleveland Medical Center, Rainbow Babies and Children's Hospital/Case Western Reserve University, Cleveland, OH, USA.
Meyerson HJ; Department of Pathology, University Hospitals Cleveland Medical Center/Case Western Reserve University, Cleveland, OH, USA.
Pokaż więcej
Źródło :
British journal of haematology [Br J Haematol] 2020 Oct; Vol. 191 (2), pp. e61-e64. Date of Electronic Publication: 2020 Jul 29.
Typ publikacji :
Case Reports; Clinical Trial; Letter
MeSH Terms :
Cord Blood Stem Cell Transplantation*
Histone-Lysine N-Methyltransferase*/genetics
Histone-Lysine N-Methyltransferase*/metabolism
Myeloid-Lymphoid Leukemia Protein*/genetics
Myeloid-Lymphoid Leukemia Protein*/metabolism
Oncogene Proteins, Fusion*/genetics
Oncogene Proteins, Fusion*/metabolism
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma*/genetics
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma*/metabolism
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma*/pathology
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma*/therapy
Antibodies, Bispecific/*administration & dosage
Allografts ; Consolidation Chemotherapy ; Humans ; Infant ; Male
Raport
Tytuł :
High-risk B-cell acute lymphoblastic leukaemia presenting with hypereosinophilia and acquiring a novel PAX5 fusion on relapse.
Autorzy :
McClure BJ; Cancer Program, Precision Medicine Theme, South Australian Health & Medical Research Institute (SAHMRI), Adelaide, SA, Australia.; School of Medicine, University of Adelaide, Adelaide, SA, Australia.
Heatley SL; Cancer Program, Precision Medicine Theme, South Australian Health & Medical Research Institute (SAHMRI), Adelaide, SA, Australia.; School of Medicine, University of Adelaide, Adelaide, SA, Australia.; Australian and New Zealand Children's Oncology Group (ANZCHOG), Clayton, VIC, Australia.
Rehn J; Cancer Program, Precision Medicine Theme, South Australian Health & Medical Research Institute (SAHMRI), Adelaide, SA, Australia.; Faculty of Health and Medical Science, University of Adelaide, Adelaide, SA, Australia.
Breen J; Faculty of Health and Medical Science, University of Adelaide, Adelaide, SA, Australia.; Computational and Systems Biology Program, SAHMRI, Adelaide, SA, Australia.; Robinson Research Institute, University of Adelaide, Adelaide, SA, Australia.
Sutton R; Australian and New Zealand Children's Oncology Group (ANZCHOG), Clayton, VIC, Australia.; Molecular Diagnostics, Children's Cancer Institute, Sydney, NSW, Australia.; School of Women's and Children's Health, University of New South Wales, Sydney, NSW, Australia.; Department of Haematology, Royal Adelaide Hospital and SA Pathology, Adelaide, SA, Australia.
Hughes TP; Cancer Program, Precision Medicine Theme, South Australian Health & Medical Research Institute (SAHMRI), Adelaide, SA, Australia.; School of Medicine, University of Adelaide, Adelaide, SA, Australia.; Department of Haematology, Royal Adelaide Hospital and SA Pathology, Adelaide, SA, Australia.; Australasian Leukaemia and Lymphoma Group, North Adelaide, SA, Australia.
Suppiah R; Women's and Children's Hospital, North Adelaide, SA, Australia.
Revesz T; Australian and New Zealand Children's Oncology Group (ANZCHOG), Clayton, VIC, Australia.; Women's and Children's Hospital, North Adelaide, SA, Australia.; School of Biological Sciences, University of Adelaide, Adelaide, SA, Australia.
Osborn M; Australian and New Zealand Children's Oncology Group (ANZCHOG), Clayton, VIC, Australia.; Australian Genomics Health Alliance (AGHA), Parkville, VIC, Australia.; Department of Haematology, Royal Adelaide Hospital and SA Pathology, Adelaide, SA, Australia.; Women's and Children's Hospital, North Adelaide, SA, Australia.
White D; Faculty of Health and Medical Science, University of Adelaide, Adelaide, SA, Australia.; Women's and Children's Hospital, North Adelaide, SA, Australia.
Yeung DT; Cancer Program, Precision Medicine Theme, South Australian Health & Medical Research Institute (SAHMRI), Adelaide, SA, Australia.; School of Medicine, University of Adelaide, Adelaide, SA, Australia.; Department of Haematology, Royal Adelaide Hospital and SA Pathology, Adelaide, SA, Australia.
White DL; Cancer Program, Precision Medicine Theme, South Australian Health & Medical Research Institute (SAHMRI), Adelaide, SA, Australia.; School of Medicine, University of Adelaide, Adelaide, SA, Australia.; Australian and New Zealand Children's Oncology Group (ANZCHOG), Clayton, VIC, Australia.; Australian Genomics Health Alliance (AGHA), Parkville, VIC, Australia.; School of Biological Sciences, University of Adelaide, Adelaide, SA, Australia.; School of Pediatrics, University of Adelaide, Adelaide, SA, Australia.
Pokaż więcej
Źródło :
British journal of haematology [Br J Haematol] 2020 Oct; Vol. 191 (2), pp. 301-304. Date of Electronic Publication: 2020 Jul 30.
Typ publikacji :
Case Reports; Letter; Research Support, Non-U.S. Gov't
MeSH Terms :
Hypereosinophilic Syndrome*/genetics
Hypereosinophilic Syndrome*/metabolism
Hypereosinophilic Syndrome*/pathology
Immunoglobulin Heavy Chains*/genetics
Immunoglobulin Heavy Chains*/metabolism
Interleukin-3*/genetics
Interleukin-3*/metabolism
Oncogene Proteins, Fusion*/genetics
Oncogene Proteins, Fusion*/metabolism
PAX5 Transcription Factor*/genetics
PAX5 Transcription Factor*/metabolism
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma*/genetics
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma*/metabolism
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma*/pathology
Adolescent ; Humans ; Male
Raport

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies